EUVIMEDEUVIMED entdecken
Open Access

Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study

Jin Ge, Aryana T Far, Jean C Digitale, Mark J Pletcher, Jennifer C Lai, National COVID Cohort Collaborative (N3C) Consortium

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.07.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Jin Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, California. Electronic …. Hauptthemen laut MEDLINE: COVID-19, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIGMS NIH HHS, CLC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The virulence and severity of SARS-CoV-2 infections have decreased over time in the general population due to vaccinations and improved antiviral treatments. Whether a similar trend has occurred in patients with cirrhosis is unclear. We used the National COVID Cohort Collaborative (N3C) to describe the outcomes over time. METHODS: We utilized the N3C level 3 data set with uncensored dates to identify all patients with chronic liver disease (CLD) with and without cirrhosis who had SARS-CoV-2 infection as of November 2023. We described the observed 30-day case fatality rate (CFR) by month of infection. We used adjusted survival analyses to calculate relative hazard of death by month of infection compared with infection at the onset of the COVID-19 pandemic. RESULTS: We identified 117,811 total patients with CLD infected with SARS-CoV-2 between March 2020 and November 2023: 27,428 (23%) with cirrhosis and 90,383 (77%) without cirrhosis. The observed 30-day CFRs during the entire study period were 1.1% (1016) for patients with CLD without cirrhosis and 6.3% (1732) with cirrhosis. Observed 30-day CFRs by month of infection varied throughout the pandemic and showed a sustained downward trend since 2022. Compared with infection in Quarter 2 of 2020 (at the beginning of the pandemic), the adjusted hazards of death at 30 days for infection in Quarter 3 of 2023 were 0.20 (95% confidence interval [CI], 0.08-0.50) for patients with CLD without cirrhosis and 0.35 (95% CI, 0.18-0.69) for patients with CLD with cirrhosis. CONCLUSIONS: In this N3C study, we found that the observed 30-day CFR decreased progressively for patients with CLD both with and without cirrhosis, consistent with broader trends seen in the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Liver CirrhosisHumansMaleFemaleMiddle AgedAgedSARS-CoV-2United StatesCohort StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

COVID-19Chronic Liver DiseaseCirrhosisSARS-CoV-2

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, California. Electronic address: jin.ge@ucsf.edu.
  • Division of Gastroenterology and Hepatology, Department of Medicine, University of California - San Francisco, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California - San Francisco, San Francisco, California.

Förderung

  • NCATS NIH HHS
  • NIGMS NIH HHS
  • CLC NIH HHS
  • NIA NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • ORFDO NIH HHS
  • NIDA NIH HHS

Zitieren

APA

Ge, J., Far, A. T., Digitale, J. C., Pletcher, M. J., Lai, J. C., & National COVID Cohort Collaborative (N3C) Consortium (2025). Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.07.028

Vancouver

Ge J, Far AT, Digitale JC, Pletcher MJ, Lai JC, National COVID Cohort Collaborative (N3C) Consortium. Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.07.028

BibTeX
@article{Ge2025,
  author = {Ge, Jin and Far, Aryana T and Digitale, Jean C and Pletcher, Mark J and Lai, Jennifer C and National COVID Cohort Collaborative (N3C) Consortium, National COVID Cohort Collaborative (N3C) Consortium},
  title = {Decreasing Case Fatality Rates for Patients With Cirrhosis Infected With SARS-CoV-2: A National COVID Cohort Collaborative Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.07.028}
}
Kostenlos starten →